Noxopharm Ltd. · ASX:NOX
Noxopharm — ShareCafe Micro/Small Cap Hidden Gems Webinar January 2021
16 slides from Noxopharm's conference presentation, Jan 28, 2021
Slide 1: Noxopharm To Present to ShareCafe Hidden Gems Webinar
ASX Announcement | 28 January 2021 Noxopharm Limited (ASX:NOX) Noxopharm To Present to ShareCafe “Hidden Gems” Webinar 28 January 2021 Sydney, Australia: Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides a copy of the presentation to be made by the Company’s C
Slide 2: Media Enquiries / Forward Looking Statements
Media Enquiries Julia Maguire The Capital Network E: julia@thecapitalnetwork.com.au T: + 61 2 8999 3699 Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”,
Slide 3: Noxopharm Limited (ASX:NOX) ShareCafe Hidden Gems January 2021
Noxopharm Limited (ASX:NOX) SHARE CAFE Hidden Gems January 2021 Discover Develop Dr Graham Kelly CEO and Managing Director Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectations reflected in the forward looking statements be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an in
Slide 5: Introduction to CEO corporate track record
Introduction to CEO corporate track record Founded Market Peak market cap Founded Novogen 1994 ASX; NASDAQ A$880m 2004 [now Kazia Therapeutics ] ~A$170m 2021 Founded Marshall Edwards Inc 2002 NASDAQ A$600m 2003 [now MEI Pharma Inc] ~A$450m 2021 Founded Noxopharm Ltd 2016 ASX A$171m 2021 Founded Nyra
Slide 6: Key metrics
Key metrics as at 27 January 2021 Market cap A$171m News Flow (next 6 months) • 3x Phase I/II and Phase II clinical cancer Share price A$0.66 trials • 1x COVID-19 clinical trial Issued cap ~258M shares • Growing first-in-class drug pipeline • Pharmorage (subsidiary) dedicated to Cash ~A$23m (31 Dec
Slide 7: Veyonda breakthrough multiple-acting immunotherapy drug
Veyonda® breakthrough mulVple-acVng immunotherapy drug 5 Blocks 1 autophagy Activates increasing immune immune cells activation 4 2 Inhibits Increases inflammation trafficking of activated immune cells Source: Dana-Faber Cancer Institute 3 Converts COLD tumors to HOT tumors NOXOPHARM LIMITED (ASX:NO
Slide 8: Veyonda Clinical program
Veyonda® Clinical program IONIC-1 Phase I/II trial Veyonda + Opdivo® (Bristol Myers Squibb) DARRT-2 Phase II trial Veyonda + external radiotherapy LuPIN-1 Phase II trial Veyonda + 177Lu-PSMA (Novar3s) NOXCOVID-1 Phase I/II trial Veyonda NOXOPHARM LIMITED (ASX:NOX) 6
Slide 9: Veyonda Focus on LuPIN-1 today
Veyonda® Focus on LuPIN-1 today IONIC-1 Phase I/II trial Veyonda + Opdivo® (Bristol Myers Squibb) DARRT-2 Phase II trial Veyonda + external radiotherapy LuPIN-1 Phase I/II trial Veyonda + Lu-PSMA (Novartis) NOXCOVID-1 Phase I/II trial Veyonda + standard of care NOXOPHARM LIMITED (ASX:NOX) 7
Slide 10: An exciting new treatment for prostate cancer
An exciting new treatment for prostate cancer 177lute3um-PSMA-617. A radiopharmaceu/cal drug Acquired by Novartis in 2018 in a ~A$9 billion deal A new treatment for prostate cancer once the cancer has spread widely and has stopped responding to chemotherapy Drug injected intravenously to deliver a d
Slide 11: Incidence
Late-stage prostate cancer rarely curable New treatments providing longer survival 8mes urgently needed Prostate cancer is the fiAh leading cause of Prostate Cancer – Mortality by Age Category (number of cases per 100,000 populaion) death in men worldwide 800 Responsible for estimated 360,000 deaths
Slide 12: LuPIN Study
LuPIN Study As promising as 177Lu-PSMA-617 is, about one-third of men don’t respond, and in those that do respond, they obtain (on average) about 6-8 months extra life QUESTION: would adding Veyonda with its immunotherapy func/ons, boost the effec/veness of the Novar/s drug, with more men responding
Slide 13: LuPIN: Interim Survival Data
LuPIN: Interim Survival Data Median overall survival = time when half the patients have died and half still alive Three standard lines of drug therapy once prostate 1st line 2nd line 3rd line End-stage cancer becomes metastatic Historical data1 ~ 8.5 months ~ 4.5 months 177 Lu-PSMA-617 alone2 13.5 m
Slide 14: LuPIN: Next Interim Data Reporting
LuPIN: Next Interim Data Reporting American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 11-13 2021 32 men Median Overall Survival: Combination was 400 + 800 mg Veyonda 17.1 months well tolerated Reported Feb 2020 a remarkable result for this late stage of the disease 56 men ? A
Slide 15: Advanced prostate cancer: Attracting Significant Pharma Interest
Advanced prostate cancer: Attracting Significant Pharma Interest Recent deals 2016 2018 2017 Price US$14 billion US$2.1 billion US$3.9 billion NOXOPHARM LIMITED (ASX:NOX) 13
Slide 16: For further information
For further information email: info@noxopharm.com web: www.noxopharm.com twitter: @noxopharm Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 14
Noxopharm — ShareCafe Micro/Small Cap Hidden Gems Webinar January 2021 on 6ix